leisure time -WSS

leisure time

author：hotspot 2025-09-30 18:42:48 - browse：5

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

hotspot

focus

WSS

Why a market frenzy over new weight loss drugs defies logic

Kansas bar where gunfire wounded 9 last month closes permanently

Smaller biotechs seek to piggyback on weight loss drug boom

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

leisure time

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Jerome Adams on the need for new antivirals for Covid

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Sports medicine is finally prioritizing gender equality

Sweden knocks USA out of World Cup in penalty kicks

Tori Bowie and the unacceptable rates of Black maternal death

STAT Readout: Friday, Oct. 20 biotech updates

Medical records are filled with copy

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Sage considers ways to reduce costs following FDA rejection

St. Louis police protesters begin picking up checks in $4.9 million settlement

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Readout LOUD podcast: Live from the 2023 STAT Summit

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

hotspot

focus

explore

leisure time